Skip to main content
Ulisse Biomed logo

Ulisse Biomed — Investor Relations & Filings

Ticker · UBM ISIN · IT0005451213 LEI · 815600F9C180B297BE35 XMIL Professional, scientific and technical activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-10-09 Capital/Financing Update
Country IT Italy
Listing XMIL UBM

About Ulisse Biomed

https://www.ulissebiomed.com/

Ulisse Biomed is a healthcare biotechnology company specializing in distributed and connected diagnostic solutions. The company develops an integrated platform that includes miniaturized qPCR instruments, an AI-driven cloud-based software, and advanced multiplexing reagents. This technology enables genetic testing for a wide range of users, from large clinical and diagnostic laboratories to smaller, peripheral labs in industrial settings. Its primary markets are healthcare and diagnostics, serving hospitals and clinics, and the agrifood and nutraceutical sectors. The company also provides OEM and development services. In late 2025, shareholders approved a proposal to change the corporate name to Helyx Industries S.p.A.

Recent filings

Filing Released Lang Actions
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Capital/Financing Update Classification · 1% confidence The document is an official communication from Ulisse Biomed S.p.A. titled "COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE" (Communication of Share Capital Variation). The text explicitly details the subscription of a capital increase, the issuance of new shares (n. 226.000 azioni), and presents a table showing the new and previous share capital composition, including the change in the number of shares and total capital. This directly relates to changes in the company's capital structure due to fundraising/share issuance. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2024-10-09 Italian
APERTURA DEL SESTO PERIODO DI ESERCIZIO DEI “WARRANT ULISSE BIOMED S.P.A. 2021-2026”: DAL 1 AL 31 OTTOBRE 2023
Capital/Financing Update Classification · 1% confidence The document is an official communication from Ulisse Biomed S.p.A. regarding the opening of the exercise period for their outstanding Warrants ("WARRANT ULISSE BIOMED S.P.A. 2021-2026"). It specifies the dates (October 1 to October 31, 2024), the exercise price (€2.78), and the subscription ratio (1 share per 1 warrant). This type of announcement, dealing with the mechanics of exercising financial instruments like warrants or options, is a specific corporate action. It is not a full annual report (10-K), an earnings release (ER), or a general management discussion (MDA). It most closely relates to capital structure changes or financing activities, but the specific focus on the exercise window for existing instruments points towards a specialized corporate action announcement. Since there is no direct category for 'Warrant Exercise Announcement', we must evaluate the closest fit. It is an announcement related to the issuance of new shares upon warrant exercise, which falls under Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were less specific. Given the detailed nature of the capital event (warrant exercise terms), CAP is a strong candidate. However, warrant exercise announcements often fall under general corporate actions. Reviewing the definitions, 'CAP' covers fundraising/financing activities. The exercise of warrants results in the issuance of new capital, making CAP appropriate. It is not a proxy statement (PSI), dividend notice (DIV), or director dealing (DIRS). Since this is a detailed, specific announcement about the terms of a capital instrument exercise, CAP is the most precise fit among the provided options, although RNS could also apply if CAP was deemed too broad. I will select CAP as it directly relates to the capital structure change resulting from the exercise.
2024-09-30 Italian
IL CONSIGLIO DI AMMINISTRAZIONE DI ULISSE BIOMED APPROVA LA RELAZIONE SEMESTRALE CONSOLIDATA AL 30 GIUGNO 2024
Report Publication Announcement Classification · 1% confidence The document explicitly states in the title and body that the Board of Directors approved the "Relazione semestrale consolidata al 30 giugno 2024" (Consolidated Half-Year Report as of June 30, 2024). A report covering a period shorter than a year (half-year) and providing comprehensive financial details (including income statement and balance sheet data) corresponds to an Interim/Quarterly Report. The filing code for this is 'IR'. The document is the report itself, not just an announcement of its publication (RPA/RNS), given its substantial length and detailed financial tables.
2024-09-30 Italian
INTERAMENTE SOTTOSCRITTO L’AUMENTO DI CAPITALE SOCIALE PER UN AMMONTARE COMPLESSIVO DI EURO 255.380
Capital/Financing Update Classification · 1% confidence The document is an official press release from Ulisse Biomed S.p.A. dated September 27, 2024. The subject ('Oggetto') explicitly states: 'INTERAMENTE SOTTOSCRITTO L'AUMENTO DI CAPITALE SOCIALE PER UN AMMONTARE COMPLESSIVO DI EURO 255.380' (Capital Increase fully subscribed for a total amount of Euro 255,380). The text details the issuance of new shares, the resulting change in share capital, and the subscription details by specific individuals. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance action.
2024-09-27 Italian
IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOCIALE
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Ulisse Biomed S.p.A. dated September 25, 2024. The subject ('Oggetto') explicitly states that the Board of Directors is exercising the delegation to increase the share capital ('IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOCIALE'). The text details the issuance of 226,000 new ordinary shares, the issue price, and the exclusion of pre-emptive rights for strategic partners. This action directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2024-09-25 Italian
Cambiamento sostanziale di un azionista facente parte del Patto Parasociale sottoscritto il 21 dicembre 2023
Major Shareholding Notification Classification · 1% confidence The document is an official communication from Ulisse Biomed S.p.A. dated August 5, 2024, titled 'Cambiamento sostanziale di un azionista facente parte del Patto Parasociale' (Substantial change of a shareholder party to the Shareholders' Agreement). It explicitly states it is made pursuant to Article 17 of the Euronext Growth Milan Issuers' Regulation ('ai sensi dell'art. 17 del Regolamento Emittenti Euronext Growth Milan'). This type of filing, which reports changes in significant shareholdings or changes involving parties to a shareholders' agreement, directly corresponds to the definition of a Major Shareholding Notification (MRQ). It is not an earnings release (ER), an annual report (10-K), or a proxy statement (DEF 14A/PSI).
2024-08-05 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.